J-Pharma Co., Ltd. is a biotechnology company developing new medicines that target solute carrier (SLC) transporters. The Company was listed on the Tokyo Stock Exchange Growth Market in March 2026.

This page provides a brief introduction to J-Pharma, including what we aim to achieve, what we are currently developing, and the key developments to watch going forward.

We are developing new medicines that target SLC transporters, which carry amino acids and other substances into and out of cells.

At the heart of our research is LAT1 (L-type amino acid transporter 1), an SLC transporter discovered by our founder. By developing drugs that inhibit LAT1, we aim to provide new treatment options for patients with cancer, autoimmune diseases, and other conditions where current treatments may not fully meet their needs.

LAT1 plays an important role in transporting amino acids required for cell growth and proliferation into cells. It is known to be highly expressed in cancer cells and activated immune cells.

By inhibiting LAT1, we are exploring new treatment approaches that differ from existing therapies.One of the defining features of our business is our strategy to build a broader development portfolio around LAT1, encompassing multiple compounds and multiple disease areas.

We are currently advancing the clinical development of two principal compounds: nanvuranlat (JPH203) and JPH034.

Development status as of August 2026

• Nanvuranlat (JPH203)

Nanvuranlat is our lead LAT1 inhibitor and is currently being evaluated in the global Phase III Beacon-BTC trial as a second-line treatment for unresectable advanced or recurrent biliary tract cancer.

We are initially seeking approval in the second-line setting while also exploring nanvuranlat's potential in first-line treatment. An investigator-initiated clinical trial is underway to evaluate nanvuranlat in combination with an ICI during the maintenance phase of first-line treatment for biliary tract cancer.

• JPH034

JPH034 is also a LAT1 inhibitor, but unlike nanvuranlat, it has demonstrated high brain penetration in nonclinical studies.

Based on this profile, we are developing JPH034 for central nervous system disorders such as multiple sclerosis. A Phase 1 clinical trial is currently underway in the United States.

A single clinical trial or news announcement does not always show the full picture of where J-Pharma is headed. Our R&D strategy extends beyond the development of any one drug or indication.

Alongside the development of nanvuranlat for biliary tract cancer, we are exploring broader treatment opportunities through combination therapy with ICIs. We are also developing JPH034 for central nervous system diseases and researching next-generation LAT1 inhibitors and new therapeutic targets.

By connecting these individual initiatives, we aim to progressively expand our pipeline and translate our research and development activities into long-term business value.

When following J-Pharma’s progress, we encourage you to look not only at individual news announcements, but also at what each development means in the context of our broader R&D and business strategy.

Key areas to watch include:

• Progress of the global Phase III clinical trial of nanvuranlat
• Progress in the development of nanvuranlat in combination with ICIs
• Progress in the Phase I clinical trial of JPH034
• New clinical and research data, publications, and other scientific achievements
• Expansion of R&D and business opportunities through collaborations and partnerships
• Progress toward our next major development milestones

Each milestone is part of a broader effort to advance our R&D and business strategy.
Through our news releases, and other communications, we will continue to share not only our latest developments, but also the context behind them and how they fit into our overall strategy.

During the fiscal year ending March 2027, we also made progress in business partnerships and public funding support. Key developments included signing a non-binding licensing term sheet with a European biotech company for the commercialization of JPH034 and the selection of the global Phase III clinical trial of nanvuranlat for support under an AMED grant program, with eligibility for up to JPY 1.5 billion in funding. We invite you to follow these initiatives alongside the progress of our own research and development and clinical trials.

For more information, please visit the following pages:

• J-Pharma’s Pipeline
• Nanvuranlat and Biliary Tract Cancer
• Global Phase III Clinical Trial (Beacon-BTC)
• Clinical Trial of Nanvuranlat in Combination with an ICI
• JPH034 Phase I Clinical Trial
• Mechanism of Action of LAT1 and LAT1 Inhibitors